Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Warren

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Cancers|January 9, 2021
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Yanina Jansen, Julia Katharina Schwarze, et al.
International Journal of Molecular Sciences|September 14, 2024
A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma PatientsDomenico Mallardo, Mario Fordellone, Andrew White, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2019
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) TrialsSaranya Chumsri, Daniel J Serie, Zhuo Li, et al.
Journal of Translational Medicine|September 8, 2023
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapyDomenico Mallardo, Mario Fordellone, Andrew White, et al.
Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Nature|March 29, 2021
The spatial landscape of lung pathology during COVID-19 progressionAndré F Rendeiro, Hiranmayi Ravichandran, Yaron Bram, et al.
Molecular Oncology|January 21, 2022
Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimensCarlos Pedraz-Valdunciel, Stavros Giannoukakos, Nicolas Potie, et al.
International Journal of Molecular Sciences|November 27, 2024
ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced MelanomaDomenico Mallardo, Mario Fordellone, Margaret Ottaviano, et al.
Journal of Translational Medicine|September 30, 2022
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarizationDomenico Mallardo, Ester Simeone, Vito Vanella, et al.
Journal of Translational Medicine|November 6, 2019
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohortDiane Damotte, Sarah Warren, Jennifer Arrondeau, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Cancers|January 9, 2021
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Yanina Jansen, Julia Katharina Schwarze, et al.
International Journal of Molecular Sciences|September 14, 2024
A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma PatientsDomenico Mallardo, Mario Fordellone, Andrew White, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2019
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) TrialsSaranya Chumsri, Daniel J Serie, Zhuo Li, et al.
Journal of Translational Medicine|September 8, 2023
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapyDomenico Mallardo, Mario Fordellone, Andrew White, et al.
Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Nature|March 29, 2021
The spatial landscape of lung pathology during COVID-19 progressionAndré F Rendeiro, Hiranmayi Ravichandran, Yaron Bram, et al.
Molecular Oncology|January 21, 2022
Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimensCarlos Pedraz-Valdunciel, Stavros Giannoukakos, Nicolas Potie, et al.
International Journal of Molecular Sciences|November 27, 2024
ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced MelanomaDomenico Mallardo, Mario Fordellone, Margaret Ottaviano, et al.
Journal of Translational Medicine|September 30, 2022
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarizationDomenico Mallardo, Ester Simeone, Vito Vanella, et al.
Journal of Translational Medicine|November 6, 2019
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohortDiane Damotte, Sarah Warren, Jennifer Arrondeau, et al.
Pageof 9